<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426474</url>
  </required_header>
  <id_info>
    <org_study_id>17681</org_study_id>
    <secondary_id>J2A-MC-GZGC</secondary_id>
    <secondary_id>2020-000125-86</secondary_id>
    <nct_id>NCT04426474</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3502970 and any side&#xD;
      effects that might be associated with it. Blood tests will be done to measure how much&#xD;
      LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it&#xD;
      affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits&#xD;
      (including three overnight stays) in the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Actual">July 12, 2021</completion_date>
  <primary_completion_date type="Actual">July 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline through Follow-up (up to Day 105)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970</measure>
    <time_frame>Day 1 through Day 84: Predose up to 96 hours postdose</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve of LY3502970</measure>
    <time_frame>Day 1 through Day 84: Predose up to 96 hours postdose</time_frame>
    <description>PK: AUC of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Pharmacodynamics (PD): Change from Baseline to Week 12 in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change from Baseline to Week 12 in Fasting Insulin</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>PD: Change from Baseline to Week 12 in Fasting Insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3502970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) for at least 6 months&#xD;
&#xD;
          -  Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to&#xD;
             (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and&#xD;
             exercise alone or a stable dose of metformin for at least 3 months prior to screening&#xD;
&#xD;
          -  Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45&#xD;
             kilograms per square meter (kg/m²), inclusive&#xD;
&#xD;
          -  Have had a stable body weight for the 3 months prior to screening (less than [&lt;]5%&#xD;
             body weight change)&#xD;
&#xD;
          -  Males and females (not considered woman of childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an&#xD;
             episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  Have had any of the following within the past 6 months prior to screening: myocardial&#xD;
             infarction, unstable angina, coronary artery bypass graft, percutaneous coronary&#xD;
             intervention (diagnostic angiograms are permitted), transient ischemic attack,&#xD;
             cerebrovascular accident or decompensated congestive heart failure, or currently have&#xD;
             New York Health Association Class III or IV heart failure&#xD;
&#xD;
          -  Show evidence of hepatitis B, and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Any glucose-lowering medications other than metformin within 3 months prior to&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Unit</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7zwMq2LwDbIpQoxy04CHQ7</url>
    <description>A Study of LY3502970 in Participants With Type 2 Diabetes</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

